Stock events for Tempest Therapeutics, Inc. (TPST)
In November 2025, Tempest announced an agreement to acquire Factor Bioscience's clinical dual-CAR T programs in an all-stock transaction and an up to $8.35 million registered direct offering of common stock and a concurrent private placement of warrants. In February 2026, Tempest announced the closing of the strategic acquisition of dual-targeting CAR-T assets and laid out a strategic plan to advance these assets. Also in February 2026, positive interim results from the REDEEM-1 trial of TPST-2003 were announced, indicating a 100% overall response rate, with plans for a potential U.S. registrational study in 2026. Tempest also announced a record date for an anticipated dividend distribution of warrants to stockholders. Over the past year, the stock price has decreased by 78.74%, with a 52-week trading range between $2.12 and $12.23.
Demand Seasonality affecting Tempest Therapeutics, Inc.’s stock price
As a clinical-stage biotechnology company, Tempest Therapeutics does not experience traditional demand seasonality for its products and services. The company's revenue generation depends on research and development milestones, clinical trial progress, and potential future commercialization of its drug candidates, rather than seasonal consumer purchasing patterns.
Overview of Tempest Therapeutics, Inc.’s business
Tempest Therapeutics, Inc. (TPST) is a clinical-stage biotechnology company focused on developing small molecule therapeutics for cancer treatment. The company develops therapies that directly kill tumor cells and activate tumor-specific immunity. Its pipeline includes TPST-1120 (Amezalpat), an oral small molecule selective antagonist of PPARα, currently in a Phase 1 trial and being evaluated in a pivotal study for HCC, with a collaboration agreement with F. Hoffmann-La Roche Ltd. TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of PGE2, is in a Phase 1 trial and is being evaluated for FAP. The company also has TPST-2003, a dual-targeting CD19/BCMA CAR-T asset, TPST-2206, a dual-targeting CD70/CD70 CAR-T for renal cell carcinoma, and other pipeline candidates like TPST-3003 and TPST-3206. Additionally, they are developing an orally available inhibitor of TREX-1 designed to selectively activate the cGAS/STING pathway.
TPST’s Geographic footprint
Tempest Therapeutics, Inc. is headquartered in Brisbane, California, United States.
TPST Corporate Image Assessment
Tempest Therapeutics' brand reputation is primarily tied to its scientific advancements, clinical trial progress, and corporate partnerships. While the stock has seen a significant decline, there is no specific information detailing events that have negatively impacted its brand reputation beyond the general financial performance. Positive news, such as promising clinical trial results and strategic acquisitions, generally contributes positively to its scientific and corporate standing.
Ownership
Tempest Therapeutics, Inc. has a mix of institutional and individual owners. Major institutional shareholders include Sabby Management, Llc, Vanguard Group Inc, Geode Capital Management, Llc, BlackRock, Inc., Fmr Llc, UBS Group AG, Northern Trust Corp, Dimensional Fund Advisors Lp, DRW Securities, LLC, and Morgan Stanley. Versant Venture Management, LLC is also a notable institutional owner. Key individual insiders include Matthew Angel, Michelle Dipp, Richard Aldrich, and Brad Bolzon.
